Service Image

Risk of Ovarian Malignancy Algorithm (ROMA) - (£107)

Sample Requirements:

Blood Sample

Turnaround Time:

5 days

The Risk of Ovarian Malignancy Algorithm (ROMA) is a specialized blood test designed to assess the likelihood of ovarian cancer in women. By analyzing specific tumor markers, this profile provides a comprehensive risk evaluation, helping healthcare providers differentiate between benign and malignant ovarian conditions. The ROMA test combines levels of Cancer Antigen 125 (CA 125) and Human Epididymis Protein 4 (HE4) with patient menopausal status (ROMA-PRE for premenopausal and ROMA-POST for postmenopausal women), offering a highly accurate prediction of ovarian malignancy risk.

Indications for testing
The ROMA test is indicated for women who present with symptoms suggestive of ovarian cancer, such as persistent bloating, pelvic pain, abnormal menstruation, or a noticeable mass in the pelvic area. It is also recommended for women with a family history of ovarian or breast cancer, as well as those undergoing routine monitoring for known ovarian cysts or other gynecological abnormalities.

What can be detected?
The Risk of Ovarian Malignancy Algorithm (ROMA) helps to:

Evaluate ovarian cancer risk: By measuring CA 125 and HE4, the ROMA test assesses the likelihood of ovarian malignancy, providing valuable guidance for further diagnostic procedures such as imaging or biopsy.
Differentiate between benign and malignant conditions: ROMA helps healthcare providers distinguish between non-cancerous ovarian cysts and those that may require urgent intervention, aiding in the decision-making process.
Monitor treatment response: In women with diagnosed ovarian cancer, this test can help track disease progression and response to treatment, allowing for adjustments in care as needed.

Who is this test for?
The ROMA test is particularly useful for women at high risk of ovarian cancer due to symptoms, family history, or existing ovarian abnormalities. It is also valuable for women undergoing evaluation for pelvic masses or who are being monitored for recurrence after treatment for ovarian cancer.

Fasting requirements
No fasting is required for the ROMA test. However, it is important to follow any specific instructions provided by your healthcare provider to ensure accurate results.

Markers Included

  • Cancer Antigen 125 (CA 125)
  • Human Epididymis Protein 4 (HE4)
  • ROMA-PRE
  • ROMA-POST
Why Book This Test?
  • ✅ Rapid results delivered from certified UK Laboratory
  • ✅ Trusted By thousands of clients through out UK
  • ✅ Clear Reporting From Our Lab Technician.
  • ✅ Accessible and convenient clinic locations
  • ✅ Competitive and transparent pricing
UKAS
CQC

Our Professional Services

Our partner, Medical Diagnosis, is UKAS 15189 accredited and registered with the CQC. All tests are conducted to the highest standards of accuracy and reliability.

More About It